BridgeMD
New treatment option for Gastric Adenocarcinoma
Official title Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
ClinicalTrials.gov ID: NCT07334431
What this study is testing
What is fruquintinib＋trastuzumab + XELOX?
fruquintinib＋trastuzumab + XELOX is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for gastric adenocarcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Have fully understood the study and voluntarily signed the informed consent;
- 18-75 years old (including 18 and 75 years old);
- Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
- No previous anti-tumor treatment for metastatic diseases;
- HER2 positive;
You likely can't join if
- Failure to comply with the study protocol or study procedure;
- Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;
- Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in...
- Known presence of symptomatic central nervous system metastasis or brain metastases;
- Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment;
- Previously received allogeneic bone marrow transplantation or organ transplantation;
See the full eligibility criteria
- Have fully understood the study and voluntarily signed the informed consent;
- 18-75 years old (including 18 and 75 years old);
- Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
- No previous anti-tumor treatment for metastatic diseases;
- HER2 positive;
- Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
- Life expectancy ≥ 3 months;
- At least one measurable lesion according to RECIST version 1.1;
- The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment):
- Absolute neutrophil count ≥1.5×109/L;
- Platelet ≥100×109 /L;
- Hemoglobin ≥90g/L;
- Total bilirubin \< 1.5 ULN;
- ALT and/or AST \< 1.5 ULN ;
- Serum creatinine (Cr) \<1.5×ULN;
- Endogenous creatinine clearance ≥50ml/min;
- Female patients of childbearing age should take effective contraceptive measures;
- Good compliance, cooperate with follow-up.
- Failure to comply with the study protocol or study procedure;
- Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;
- Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
- Known presence of symptomatic central nervous system metastasis or brain metastases;
- Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment;
- Previously received allogeneic bone marrow transplantation or organ transplantation;
- Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as determined by the researcher);
- Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurs within 6 months before the start of study treatment;
- people who are allergic to the investigational drug or any of its adjuncts;
- Participated in other domestic unapproved or unmarketed drug clinical trials and accepted the corresponding experimental drug treatment within 4 weeks before enrollment;
- International Standardized Ratio (INR) \>1.5 or partially activated prothrombin time (APTT) \>1.5×ULN;
- The investigator identified clinically significant electrolyte abnormalities;
- Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
- Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);
- Had any disease or condition prior to enrollment that affected drug absorption, or the patient could not take fruquintinib orally;
- Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectosed tumors, or other conditions that may cause gastrointestinal bleeding or perforation as...
- Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months \>30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks \>5 mL of fresh...
- Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York...
- Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York...
- Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;
- Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
- Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;
- Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical...
- Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume \> 1.0g;
- Complications require long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (\> 10mg/ day prednisone or other therapeutic hormone);
- Investigators believe that the patient has any other conditions that are not suitable for participating in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Zhengzhou, Henan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zhengzhou, Henan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.